Shanghai Origincell Biological Cryo Equipment Co., Ltd. announced that it will receive CNY 410,464,000 in an equity round of funding on March 14, 2022. The transaction will include participation from Canature Health Technology Group Co., Ltd. for CNY 101,000,000, Lishui Senyuanchang Enterprise Management Center (Limited Partnership) for CNY 101,000,000, stake will increase from 9.1% to 13.61%, Shanghai Shengsen Investment Center (Limited Partnership) for CNY 20,800,000 stake will decrease from 9.7% to 8.35%, Shanghai Hongsen Investment Center (Limited Partnership) for CNY 14,998,500 stake will decrease from 6.91% to 5.96%, Shanghai Senjing Investment Center (Limited Partnership) for CNY 14,190,500 stake will decrease from 6.08% to 5.32%, Shanghai Senchun Investment Center (Limited Partnership) for CNY 13,130,000 stake will decrease from 5.32% to 4.7%, Shanghai Senliang Investment Center (Limited Partnership) for CNY 6,464,000 stake will decrease from 3.2% to 2.73%, Shanghai Senwei Investment Center (Limited Partnership) for CNY 7,575,000 stake will decrease from 2.86% to 2.56%, new investor Lishui Senyuanjia Enterprise Management Center (Limited Partnership) for CNY 50,500,000 for 3.58%, Lishui Senyuanxu Enterprise Management Center (Limited Partnership) for CNY 50,500,000 for 3.58%, Qu Jianguo for CNY 10,100,000 for 0.72%, and Deluxe Family Co., Ltd. for CNY 20,200,000 stake will increase from 1.45% to 2.46%. The registered capital of the company will increase by CNY 81,280,000.

The round is being raised at a pre-money valuation of CNY 1,000,000,000.